Emergent Biosolutions
EBS
297 hedge funds and large institutions have $2.53B invested in Emergent Biosolutions in 2018 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 106 increasing their positions, 105 reducing their positions, and 31 closing their positions.
179% more call options, than puts
Call options by funds: $3.06M | Put options by funds: $1.1M
77% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 31
8% more funds holding
Funds holding: 275 → 297 (+22)
1% more repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 105
0.34% more ownership
Funds ownership: 84.83% → 85.16% (+0.34%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
9% less capital invested
Capital invested by funds: $2.79B → $2.53B (-$260M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
+$62.5M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
+$20.6M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$19.7M |
| 4 |
ACM
Atlanta Capital Management
Atlanta,
Georgia
|
+$16.9M |
| 5 |
FA
Friess Associates
Greenville,
Delaware
|
+$16.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$21.6M |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$20M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$19.6M |
| 4 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$18.1M |
| 5 |
Renaissance Technologies
New York
|
-$17.7M |
EBS Hedge Fund Activity: Q4 2018 in Review
297 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2018, worth a combined $2.53B — down 9.3% from $2.79B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new EBS positions and 31 closed out — a net gain of 24 holders — while 106 added to existing stakes and 105 trimmed.
The largest buyer was Neuberger Berman Group, adding an estimated $62.5M. The largest seller was Acadian Asset Management, cutting an estimated $21.6M.
- 297 institutional investors held Emergent Biosolutions (EBS) as of Q4 2018, up from 275 in Q3 2018.
- Funds reported $2.53B of Emergent Biosolutions stock for Q4 2018, down 9.3% quarter-over-quarter.
- 55 funds opened new Emergent Biosolutions positions in Q4 2018 and 31 closed out, a net change of +24 holders.
- The largest Emergent Biosolutions buyer in Q4 2018 was Neuberger Berman Group, an estimated $62.5M added.
- The largest Emergent Biosolutions seller in Q4 2018 was Acadian Asset Management, an estimated $21.6M sold.
Based on aggregated 13F filings for Q4 2018.